The fact that paxalisib is well tolerated should help for the drug potential as a combination therapy. IMO. Hopefully, there is some other drug out there that could be trialled (down the track) as a combination therapy.
Paxalisib IMO is looking good as a future platform drug. Perhaps once it reaches first commercial approval then Kazia might fund further indication as a combination therapy. All speculation here. Maybe the drug can be chemically combined with something else in development.
